Literature DB >> 1479618

Analysis of the upstream regulatory region of human ventricular myosin light chain 1 gene.

Q Shi1, R K Li, D A Mickle, G Jackowski.   

Abstract

To explore the mechanisms regulating expression of ventricular myosin light chain 1, the human gene including 5'-flanking DNA was cloned and characterized by Southern blot and restriction mapping. A 2 kb 5'-flanking DNA was sequenced and linked to a chloramphenicol acetyltransferase reporter gene. The constructs then were transfected into cultured human and rat cardiomyocytes as well as rat aortic endothelial cells. Deletion analysis of constructs revealed that the basal promoter sequences, which were located within 62 base pairs of the cap site, could direct high levels of chloramphenicol acetyltransferase gene expression in the cardiomyocytes and endothelial cells. The region between -62 to -312 base pairs strongly repressed the chloramphenicol acetyltransferase gene expression in the cardiomyocytes and endothelial cells. Positive elements were found between -312 and -2000 base pairs of the cap site. These results are indicative, among other possibilities, that the human ventricular myosin light chain 1 gene is turned on in cardiomyocytes by the presence of trans-acting factors that are bound to upstream positive elements and is turned off in non-muscle cells by the presence of repressor-binding proteins. But this mechanism remains to be established.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1479618     DOI: 10.1016/0022-2828(92)93089-3

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  1 in total

1.  An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression.

Authors:  Ling Yu; Read Allen; Lin Jia; Ting Sun; Steven J Isakoff; Marielle Scherrer-Crosbie; Allison M Kehlmann; Hui Zheng; Amy Ly; Charlotte S Walmsley; Katherine Hesler; Ava N Varasteh; Christopher J Pinto; Daniel E McLoughlin; Wenjin Wu; Xinhui Wang
Journal:  Front Oncol       Date:  2022-05-03       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.